Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R37CA240707-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to learn whether an education and support program can help caregivers feel more confident in technical and communication skills needed to care for a person with cancer. Patients with cancer and their caregivers face many challenges. These include learning about cancer and its treatment, coping with symptoms from illness and treatment side effects, making adjustments to usual activities, and managing the emotional effects of having a serious illness. This study is testing whether different forms of education and support can help caregivers feel better prepared. To find out if education about caregiving and different kinds of support are effective, study personnel will compare approaches to help find ways to improve the services that are provided to caregivers during cancer treatment. About 180 patients and their caregivers at the Seidman Cancer Center will take part in this study. Participating in research is voluntary and this study is funded by the National Institute of Health.
This is a 2-group, prospective, randomized controlled design to test the effect of an intervention, as compared to a usual care control group, on family caregivers (CG) outcomes, patient outcomes, and healthcare utilization outcomes during treatment.
The objectives of this study are to:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control - Standard of Care | No Intervention | CG(caregivers)/CP(cancer patients) dyads | |
| Intervention | Experimental | CG/CP dyads
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| One-on-one support/educational sessions | Behavioral | One-on-one support/educational sessions with the caregiver during radiation treatments (note - intervention sessions 2 & 3 delivered by phone during COVID-19 and remained an option after the pandemic). |
| Measure | Description | Time Frame |
|---|---|---|
| CG Anxiety at 20 Weeks Post-treatment | Difference in CG anxiety between the intervention and control groups at 20 weeks post-radiation treatment. CG anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a. This 7-item questionnaire assesses self-reported fear, worry, anxiety, tension, nervousness, and restlessness in the family caregiver over the last 7 days. This outcome will be reporting the average T-score for anxiety as measured by the PROMIS scale. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater anxiety. For example, a T-score of 60 is one standard deviation worse anxiety than average. | 20 weeks post treatment |
| Measure | Description | Time Frame |
|---|---|---|
| CG Anxiety at Baseline | CG anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a. This 7-item questionnaire assesses self-reported fear, worry, anxiety, tension, nervousness, and restlessness in the family caregiver over the last 7 days. This outcome will be reporting the average T-score for anxiety as measured by the PROMIS scale. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater anxiety. For example, a T-score of 60 is one standard deviation worse anxiety than average. |
Not provided
Inclusion Criteria (for patients):
Inclusion Criteria (for CGs):
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Susan Mazanec, PhD, RN | Case Western Reserve University, Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | United States | ||
| MetroHealth Medical Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40299112 | Derived | Park S, Blackstone EC, Mazanec SR. Exploring the determinants of health literacy and its effects on health-related outcomes in family caregivers of patients with cancer. Support Care Cancer. 2025 Apr 29;33(5):433. doi: 10.1007/s00520-025-09494-7. | |
| 34107914 | Derived | Mazanec SR, Blackstone E, Daly BJ. Building family caregiver skills using a simulation-based intervention for care of patients with cancer: protocol for a randomized controlled trial. BMC Nurs. 2021 Jun 9;20(1):93. doi: 10.1186/s12912-021-00612-4. |
Not provided
Not provided
Family caregiver and cancer participant dyads are enrolled in this 2-group, prospective, randomized controlled design to test the effect of a caregiver intervention during radiation therapy. The study enrolled a total of 242 dyads=484 participants
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Control Group - Caregivers(CG) | Caregivers(CG) |
| FG001 | Control Group - Cancer Participants(CP) | Cancer participants(CP) |
| FG002 | Experimental Group - Caregivers(CG) | Three, one-on-one support/educational sessions with the caregiver during radiation treatment, followed by a telephone booster contact 2 weeks post-treatment. |
| FG003 | Experimental Group - Cancer Participants(CP) | Three, one-on-one support/educational sessions with the caregiver (of the caregiver-cancer patient dyad) during radiation treatment, followed by a telephone booster contact 2 weeks post-treatment. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
The Overall Number of Baseline Participants includes any participant for whom some data was collected. Not all data included in the Participant Flow was able to be collected for each participant.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Control Group - Caregivers(CG) | Caregivers(CG) |
| BG001 | Control Group - Cancer Participants(CP) | Cancer participants(CP) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Age information is missing for:
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | CG Anxiety at 20 Weeks Post-treatment | Difference in CG anxiety between the intervention and control groups at 20 weeks post-radiation treatment. CG anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a. This 7-item questionnaire assesses self-reported fear, worry, anxiety, tension, nervousness, and restlessness in the family caregiver over the last 7 days. This outcome will be reporting the average T-score for anxiety as measured by the PROMIS scale. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater anxiety. For example, a T-score of 60 is one standard deviation worse anxiety than average. | Control arm: No data collected for 27 caregivers. Intervention arm: No data collected for 34 caregivers. | Posted | Mean | Standard Deviation | T-score | 20 weeks post treatment |
|
the first week of radiation therapy to 20 weeks after treatment, about 7 months
For all-cause mortality, deaths were unrelated to the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Control Group - Caregivers(CG) | Caregivers(CG) | 0 |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Susan Mazanec, PhD, RN, Study Principal Investigator | Case Western Reserve University | 1-216-368-5533 | susan.mazanec@case.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 13, 2025 | Aug 18, 2025 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form: Caregiver Consent Form | Dec 1, 2022 | Aug 18, 2025 | ICF_001.pdf |
| ICF | No | No | Yes | Informed Consent Form: Participant Consent Form | Jun 13, 2024 | Aug 20, 2025 | ICF_002.pdf |
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Patient and family caregiver dyads are enrolled in this 2-group, prospective, randomized controlled design to test the effect of a caregiver intervention during radiation therapy.
The study enrolled a total of 484 participants(242 dyads)
Not provided
Not provided
Research Assistant (RA) will be blind to which group CG is assigned.
| Telephone booster contact | Behavioral | Telephone booster contact 2 weeks post-treatment. |
|
| Baseline |
| CG Anxiety at the End of Radiation Treatment | Difference in CG anxiety between the intervention and control groups at the end of radiation treatment CG anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a. This 7-item questionnaire assesses self-reported fear, worry, anxiety, tension, nervousness, and restlessness in the family caregiver over the last 7 days. This outcome will be reporting the average T-score for anxiety as measured by the PROMIS scale. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater anxiety. For example, a T-score of 60 is one standard deviation worse anxiety than average. | At end of treatment, average of seven weeks |
| CG Anxiety at 4 Weeks Post Treatment | CG anxiety between the intervention and control groups at 4 weeks post treatment. CG anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a. This 7-item questionnaire assesses self-reported fear, worry, anxiety, tension, nervousness, and restlessness in the family caregiver over the last 7 days. This outcome will be reporting the average T-score for anxiety as measured by the PROMIS scale. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater anxiety. For example, a T-score of 60 is one standard deviation worse anxiety than average. | 4 weeks post treatment |
| CG Depression | CG depression will be measured with the PROMIS Depression Short Form 8b. This 8-item questionnaire assesses caregiver self-reported negative mood (sadness, guilt), views of self (worthlessness), and social cognition (loneliness), as well as decreased positive affect and engagement. It assesses depression over the last 7 days. This outcome will be reporting the average T-score for depression as measured by the PROMIS scale. Raw scores range from 8 to 40. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater depression. For example, a T-score of 60 is one standard deviation worse depression than average. | at baseline, at end of treatment (average of seven weeks), and at 4 and 20 weeks post treatment |
| CG Health-related Quality of Life (HRQOL) as Measured by PROMIS Global Health Scale - Global Mental Health Domain | The PROMIS Global Health Scale will be scored as two separate domains - Global Physical Health and Global Mental Health. These domains are not combined for a total score. Raw scores range from 4 to 20. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents better health (Global Physical Health or Global Mental Health) than the general population. For example, a T-score of 60 is one standard deviation better health than average | at baseline, at end of treatment (average of seven weeks), and at 4 and 20 weeks post treatment |
| CG HRQOL as Measured by PROMIS Global Health Scale - Global Physical Health | The PROMIS Global Health Scale will be scored as two separate domains - Global Physical Health and Global Mental Health. These domains are not combined for a total score. Raw scores range from 4 to 20. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents better health (Global Physical Health or Global Mental Health) than the general population. For example, a T-score of 60 is one standard deviation better health than average | Baseline, end of treatment, 4 weeks and 20 weeks post treatment |
| CG Fatigue | CG fatigue will be measured with the PROMIS Fatigue Short Form 7a, a 7-item questionnaire that evaluates the self-reported experience of fatigue (frequency, duration, intensity) and the impact of fatigue on daily activities. It assesses fatigue over the last 7 days. This outcome will be reporting the average T-score for fatigue. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater fatigue. For example, a T-score of 60 is one standard deviation worse fatigue than average. | at baseline, at end of treatment (average of seven weeks), and at 4 and 20 weeks post treatment |
| Participant HRQOL (Cancer Patient) as Measured by FACT-G | Participant HRQOL will be measured using the disease-specific versions of FACT-G that include common subscales (physical, social, emotional, and functional well-being) plus cancer-specific questions. The effect of the intervention on HRQOL across diagnoses will be analyzed using the common subscales. The symptom experience with each diagnostic group will be described using the cancer-specific subscale. Participants rate their response to each item on a 5-point Likert-type scale. After reverse-scoring negatively worded questions, items are summed. Higher scores indicate better quality of life. The FACT - Colorectal (FACT-C, Version 4) is a 37-item questionnaire that measures self-reported HRQOL in patients with colorectal cancer over the last 7 days. | at baseline, at end of treatment (average of seven weeks), and at 4 and 20 weeks post treatment |
| Interrupted Treatment | Interrupted Radiation Treatment Course, defined as the total number of missed treatment days due to patient or caregiver reasons, will be determined from the patient's radiation therapy treatment record. Number of days of each episode of absence from treatment will also be recorded. | End of radiation treatment, average of seven weeks |
| Healthcare Utilization for Participants, as Measured by Number of Hospital Admissions | Healthcare utilization was measured by number of hospital admissions during the entire study period. These were assessed via review of the patient's medical record at T4 (end of study). | 20 weeks post treatment |
| Healthcare Utilization for Participants, as Measured by Number of Emergency Room Visits | Healthcare utilization was measured by number of emergency room visits during the entire study period. These were assessed via review of the patient's medical record at T4 (end of study). | 20 weeks post treatment |
| Healthcare Utilization for Participants, as Measured by Number of Visits for IV Hydration | Healthcare utilization was measured by number of visits for IV hydration during the entire study period. These were assessed via review of the patient's medical record at T4 (end of study). | 20 weeks post treatment |
| Cleveland |
| Ohio |
| 44109 |
| United States |
| Death |
|
| Lost to Follow-up |
|
| Physician Decision |
|
| Unable to complete due to the drop out of the corresponding dyad |
|
| BG002 | Experimental Group - Caregivers(CG) | Three, one-on-one support/educational sessions with the caregiver during radiation treatment, followed by a telephone booster contact 2 weeks post-treatment. |
| BG003 | Experimental Group - Cancer Participants(CP) | Three, one-on-one support/educational sessions with the caregiver (of the caregiver-cancer patient dyad) during radiation treatment, followed by a telephone booster contact 2 weeks post-treatment. |
| BG004 | Total | Total of all reporting groups |
Age information is missing for:
|
| Count of Participants |
| Participants |
|
| Sex: Female, Male | Biological sex information is missing for:
| Biological sex information is missing for:
| Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Ethnicity information missing for: - 1 CG in control arm | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Race/ethnicity information missing for:
| Count of Participants | Participants |
|
| Control - Standard of Care |
CG(caregivers)/CP(cancer patients) dyads |
| OG001 | Intervention | CG/CP dyads - Three, one-on-one support/educational sessions with the caregiver during radiation treatment, followed by a telephone booster contact 2 weeks post-treatment. One-on-one support/educational sessions: One-on-one support/educational sessions with the caregiver during radiation treatments (note - intervention sessions 2 & 3 delivered by phone during COVID-19 and remained an option after the pandemic) Telephone booster contact: Telephone booster contact 2 weeks post-treatment. |
|
|
| Secondary | CG Anxiety at Baseline | CG anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a. This 7-item questionnaire assesses self-reported fear, worry, anxiety, tension, nervousness, and restlessness in the family caregiver over the last 7 days. This outcome will be reporting the average T-score for anxiety as measured by the PROMIS scale. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater anxiety. For example, a T-score of 60 is one standard deviation worse anxiety than average. | Posted | Mean | Standard Deviation | T-score | Baseline |
|
|
|
| Secondary | CG Anxiety at the End of Radiation Treatment | Difference in CG anxiety between the intervention and control groups at the end of radiation treatment CG anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a. This 7-item questionnaire assesses self-reported fear, worry, anxiety, tension, nervousness, and restlessness in the family caregiver over the last 7 days. This outcome will be reporting the average T-score for anxiety as measured by the PROMIS scale. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater anxiety. For example, a T-score of 60 is one standard deviation worse anxiety than average. | Control group: Data not collected for 16 caregivers. Intervention group: Data not collected for 10 caregivers. | Posted | Mean | Standard Deviation | T-score | At end of treatment, average of seven weeks |
|
|
|
| Secondary | CG Anxiety at 4 Weeks Post Treatment | CG anxiety between the intervention and control groups at 4 weeks post treatment. CG anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a. This 7-item questionnaire assesses self-reported fear, worry, anxiety, tension, nervousness, and restlessness in the family caregiver over the last 7 days. This outcome will be reporting the average T-score for anxiety as measured by the PROMIS scale. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater anxiety. For example, a T-score of 60 is one standard deviation worse anxiety than average. | Control group: Data not collected for 9 caregivers. Intervention group: Data not collected for 8 caregivers. | Posted | Mean | Standard Deviation | T-score | 4 weeks post treatment |
|
|
|
| Secondary | CG Depression | CG depression will be measured with the PROMIS Depression Short Form 8b. This 8-item questionnaire assesses caregiver self-reported negative mood (sadness, guilt), views of self (worthlessness), and social cognition (loneliness), as well as decreased positive affect and engagement. It assesses depression over the last 7 days. This outcome will be reporting the average T-score for depression as measured by the PROMIS scale. Raw scores range from 8 to 40. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater depression. For example, a T-score of 60 is one standard deviation worse depression than average. | Data not collected for:
| Posted | Mean | Standard Deviation | T-score | at baseline, at end of treatment (average of seven weeks), and at 4 and 20 weeks post treatment |
|
|
|
| Secondary | CG Health-related Quality of Life (HRQOL) as Measured by PROMIS Global Health Scale - Global Mental Health Domain | The PROMIS Global Health Scale will be scored as two separate domains - Global Physical Health and Global Mental Health. These domains are not combined for a total score. Raw scores range from 4 to 20. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents better health (Global Physical Health or Global Mental Health) than the general population. For example, a T-score of 60 is one standard deviation better health than average | Data not collected for:
| Posted | Mean | Standard Deviation | T-score | at baseline, at end of treatment (average of seven weeks), and at 4 and 20 weeks post treatment |
|
|
|
| Secondary | CG HRQOL as Measured by PROMIS Global Health Scale - Global Physical Health | The PROMIS Global Health Scale will be scored as two separate domains - Global Physical Health and Global Mental Health. These domains are not combined for a total score. Raw scores range from 4 to 20. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents better health (Global Physical Health or Global Mental Health) than the general population. For example, a T-score of 60 is one standard deviation better health than average | Data not collected for:
| Posted | Mean | Standard Deviation | T-score | Baseline, end of treatment, 4 weeks and 20 weeks post treatment |
|
|
|
| Secondary | CG Fatigue | CG fatigue will be measured with the PROMIS Fatigue Short Form 7a, a 7-item questionnaire that evaluates the self-reported experience of fatigue (frequency, duration, intensity) and the impact of fatigue on daily activities. It assesses fatigue over the last 7 days. This outcome will be reporting the average T-score for fatigue. Raw scores range from 7 to 35. Each participant's raw score on the scale will be converted to a standardized T-score that has a mean of 50 and a standard deviation of 10. A higher T-score represents greater fatigue. For example, a T-score of 60 is one standard deviation worse fatigue than average. | Data not collected for:
| Posted | Mean | Standard Deviation | T-score | at baseline, at end of treatment (average of seven weeks), and at 4 and 20 weeks post treatment |
|
|
|
| Secondary | Participant HRQOL (Cancer Patient) as Measured by FACT-G | Participant HRQOL will be measured using the disease-specific versions of FACT-G that include common subscales (physical, social, emotional, and functional well-being) plus cancer-specific questions. The effect of the intervention on HRQOL across diagnoses will be analyzed using the common subscales. The symptom experience with each diagnostic group will be described using the cancer-specific subscale. Participants rate their response to each item on a 5-point Likert-type scale. After reverse-scoring negatively worded questions, items are summed. Higher scores indicate better quality of life. The FACT - Colorectal (FACT-C, Version 4) is a 37-item questionnaire that measures self-reported HRQOL in patients with colorectal cancer over the last 7 days. | Data not collected for:
| Posted | Mean | Standard Deviation | score on a scale | at baseline, at end of treatment (average of seven weeks), and at 4 and 20 weeks post treatment |
|
|
|
| Secondary | Interrupted Treatment | Interrupted Radiation Treatment Course, defined as the total number of missed treatment days due to patient or caregiver reasons, will be determined from the patient's radiation therapy treatment record. Number of days of each episode of absence from treatment will also be recorded. | Posted | Median | Full Range | days | End of radiation treatment, average of seven weeks |
|
|
|
| Secondary | Healthcare Utilization for Participants, as Measured by Number of Hospital Admissions | Healthcare utilization was measured by number of hospital admissions during the entire study period. These were assessed via review of the patient's medical record at T4 (end of study). | Posted | Median | Full Range | admissions | 20 weeks post treatment |
|
|
|
| Secondary | Healthcare Utilization for Participants, as Measured by Number of Emergency Room Visits | Healthcare utilization was measured by number of emergency room visits during the entire study period. These were assessed via review of the patient's medical record at T4 (end of study). | Posted | Median | Full Range | visits | 20 weeks post treatment |
|
|
|
| Secondary | Healthcare Utilization for Participants, as Measured by Number of Visits for IV Hydration | Healthcare utilization was measured by number of visits for IV hydration during the entire study period. These were assessed via review of the patient's medical record at T4 (end of study). | Posted | Median | Full Range | visits | 20 weeks post treatment |
|
|
|
| 117 |
| 0 |
| 117 |
| 0 |
| 117 |
| EG001 | Control Group - Cancer Participants(CP) | Cancer participants(CP) | 9 | 117 | 0 | 117 | 0 | 117 |
| EG002 | Experimental Group - Caregivers(CG) | Three, one-on-one support/educational sessions with the caregiver during radiation treatment, followed by a telephone booster contact 2 weeks post-treatment. | 0 | 125 | 0 | 125 | 0 | 125 |
| EG003 | Experimental Group - Cancer Participants(CP) | Three, one-on-one support/educational sessions with the caregiver (of the caregiver-cancer patient dyad) during radiation treatment, followed by a telephone booster contact 2 weeks post-treatment. | 9 | 125 | 0 | 125 | 0 | 125 |
Not provided
Not provided
Not provided
|
|
|
|
|
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
|
|
|
|
|
| End of radiation treatment |
|
|
| 4 weeks post radiation treatment |
|
|
| 20 weeks post radiation treatment |
|
|
| End of treatment |
|
|
| 4 weeks post treatment |
|
|
| 20 weeks post treatment |
|
|
| End of radiation treatment |
|
|
| 4 weeks post treatment |
|
|
| 20weeks post treatment |
|
|
| End of treatment |
|
|
| 4 weeks post treatment |
|
|
| 20 weeks post treatment |
|
|
| End of treatment |
|
|
| 4 weeks post radiation treatment |
|
|
| 20 weeks post radiation treatment |
|
|